Johnson & Johnson (J&J) subsidiary Janssen Research & Development has signed a collaborative research agreement with Aldeyra Therapeutics for the development of new drugs to treat systemic inflammatory diseases.
Formed through Johnson & Johnson Innovation, the alliance aims to work on a new therapeutic target class called pro-inflammatory aldehyde mediators.
Go deeper with GlobalData
Aldeyra is reported to have already validated its new drug candidate reproxalap, which belongs to its aldehyde sequestration platform, for anti-inflammatory activity in four Phase II clinical trials.
The latest deal is intended to develop existing reproxalap analogues for treating patients suffering from inflammatory diseases.
These analogues include reproxalap ocular of 0.1% and 0.25% strength for dry eye disease, 0.25% and 0.5% for allergic conjunctivitis and 0.5% for non-infectious anterior uveitis, along with 1% reproxalap dermal for sjögren-larsson syndrome.
Aldeyra Therapeutics president and CEO said: “As we are committed to the development of novel therapeutic product candidates for autoimmune and other diseases characterised by systemic inflammation, we are pleased to partner with Janssen, a world leader in the discovery and development of therapeutics for inflammatory diseases.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAs per the collaboration agreement, both Aldeyra and Janssen will be involved in research activities that are set to be regulated by a joint scientific review committee.
In addition, Janssen will hold an option to negotiate an exclusive licence related to the compounds that will be developed during the partnership. The option is valid for a specific period and is subject to certain conditions.
